Search Results
Your search for The ASCO Post Staff,The ASCO Post Staff matches 6165 pages
Showing 5251 - 5300H. Timothy Hsiao, PhD, Joins the American Society for Radiation Oncology as Director of Scientific Affairs
The American Society for Radiation Oncology (ASTRO) recently welcomed H. Timothy Hsiao, PhD, as its new Director of Scientific Affairs, where he will provide strategic leadership to advance the impact of research and innovation in radiation oncology through ASTRO’s research funding, fellowships,...
Translational Research in Oncology Appoints Peter Fasching, MD, and Hari Kumar, PhD, to Board of Directors
TRANSLATIONAL RESEARCH IN ONCOLOGY (TRIO), a global academic clinical research organization, recently announced the appointment of two new members to the Company’s Board of Directors. Joining the board are Peter Fasching, MD, and Hari Kumar, PhD. Together, they bring decades of leadership in key...
Rush University Medical Center Earns National Center of Excellence for Pancreatic Cancer Designation
The National Pancreas Foundation has named Rush University Medical Center as a National Center of Excellence for Pancreatic Cancer, a designation given to hospitals that have demonstrated the multidisciplinary approach, social support, and advanced research resources needed to successfully treat...
Richard L. Schilsky, MD, FACP, FSCT, FASCO, Designated a National Associate of the National Academies of Sciences, Engineering, and Medicine
In February 2020, Richard L. Schilsky, MD, FACP, FSCT, FASCO, Chief Medical Officer and Executive Vice President of ASCO, was designated a National Associate of the National Academy of Sciences, Engineering, and Medicine for his decades-long contributions to the National Academy of Medicine (NAM). ...
FDA Pipeline: Priority Review in DLBCL, Fast Track Designations in T-Cell Lymphoma and Adenoid Cystic Carcinoma
Over the past week, the U.S. Food and Drug Administration (FDA) granted Priority Review to a combination therapy in diffuse large B-cell lymphoma (DLBCL); gave Fast Track designations for treatments in T-cell lymphoma and adenoid cystic carcinoma; granted Orphan Drug designation to an agent for the ...
NSABP B-42 Trial 10-Year Update: Impact of Extended Letrozole on Disease-Free Survival
“In the 10-year analysis of the NSABP B-42 trial, the effect of extended treatment with 5 years of letrozole on disease-free survival persisted and reached statistical significance. There was no significant improvement in overall survival with letrozole, but letrozole continued to provide a...
Investigators in Brazil Explore Availability, Cost, and Use of Biosimilar Trastuzumab in Patients With HER2-Positive Breast Cancer
Investigators in Brazil are seeking to explore the efficacy and safety of adjuvant biosimilar trastuzumab in a real-world study of patients with early HER2-positive breast cancer. In 2019, biosimilar trastuzumab became the first biosimilar approved in Brazil for the treatment of patients with...
Expert Point of View: Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH, Assistant Professor of Medicine at Harvard Medical School and Associate Director of the Susan F. Smith Center for Women’s Cancers at Dana-Farber/Brigham and Women’s Cancer Center, Boston, commented on KEYNOTE-890. “Previous work has suggested minimal activity of...
Small Study Explores Impact of Novel Regimen on Pembrolizumab for Triple-Negative Breast Cancer
In the phase II KEYNOTE-890 trial, patients with inoperable advanced triple-negative breast cancer who received one intratumoral tavokinogene telseplasmid injection followed by electroporation and pembrolizumab, several patients with skin or subcutaneous tumors saw metastatic lesions disappear,...
Phase III SOPHIA Trial Evaluates Margetuximab/Chemotherapy vs Trastuzumab/Chemotherapy for HER2-Positive Breast Cancer
The second interim analysis of the phase III SOPHIA trial demonstrated a significant though modest improvement in progression-free survival, response rate, and clinical benefit with the addition of margetuximab to chemotherapy vs trastuzumab plus chemotherapy in patients with HER2-positive...
Phase III KEYNOTE-522: Pembrolizumab Benefits Outcome in Neoadjuvant, Adjuvant Settings in Triple-Negative Breast Cancer
In patients with triple-negative breast cancer, the addition of pembrolizumab to neoadjuvant and adjuvant chemotherapy achieves higher rates of pathologic complete response compared with placebo, according to results of the phase III KEYNOTE-522 trial presented at the 2019 San Antonio Breast Cancer ...
Adding Capecitabine to Systemic Therapies Improves Outcomes in Triple-Negative Breast Cancer
Capecitabine improves disease-free and overall survival for patients with triple-negative breast cancer, but only when it is added to other systemic therapies, not when it is used as a substitute, according to a large meta-analysis of the effects of capecitabine in early breast cancer, The results...
Expert Point of View: A. Jo Chien, MD
A. Jo Chien, MD, Associate Professor at UCSF’s Helen Diller Comprehensive Cancer Center, San Francisco, was the formal discussant of this abstract. Dr. Chien said that a median follow-up of 3-years is relatively short for this trial, considering about 75% of patients had hormone receptor–positive...
Adjuvant Ado-Trastuzumab Emtansine vs Paclitaxel Plus Trastuzumab in Early HER2-Positive Breast Cancer
Results of the randomized, phase II ATEMPT trial showed that the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) failed to demonstrate improved safety when compared with paclitaxel plus trastuzumab as adjuvant therapy in patients with stage 1 HER2-positive breast cancer. These results of...
Expert Point of View: Steven J. Isakoff, MD, PhD
Steven J. Isakoff, MD, PhD, a medical oncologist at Massachusetts General Hospital, Boston, commented on the results of the DESTINY-Breast01 trial. “These data are extraordinarily encouraging, suggesting we will have another new option for patients with metastatic HER2-positive breast cancer. The...
Phase II DESTINY-Breast01: T-DXd Effective in Pretreated, Metastatic HER2-Positive Breast Cancer
In heavily pretreated patients with HER2-positive metastatic breast cancer [fam-]trastuzumab deruxtecan-nxki (T-DXd), a novel antibody-drug conjugate, achieved high response rates and durable responses, according to results of the phase II DESTINY-Breast01 trial presented at the 2019 San Antonio...
Expert Point of View: Steven J. Isakoff, MD, PhD
“With longer follow-up, the addition of pertuzumab to chemotherapy and trastuzumab appears to show benefit in hormone receptor–positive patients as well. In practice, we offer this regimen to node-positive patients and we are encouraged that hormone receptor-positive and -negative patients have a...
Chemotherapy, Trastuzumab, and Pertuzumab in Early HER2-Positive, Node-Positive Breast Cancer: Six-Year Follow-up of APHINITY Trial
Martine J. Piccart, MD, PhD, FASCO, reported that at 6-year follow-up of the APHINITY trial there was a modest, but not statistically significant, overall survival benefit for the addition of pertuzumab to chemotherapy plus trastuzumab vs chemotherapy/trastuzumab as adjuvant therapy in patients...
Phase III HER2CLIMB Trial Yields Positive Data in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis
The investigational oral agent tucatinib added to trastuzumab/capecitabine reduced the risk of death by one-third and reduced the risk of disease progression or death by one-half in patients with heavily pretreated metastatic HER2-positive breast cancer, including those with untreated or previously ...
Pulmonary Pathology of Early COVID-19 Pneumonia Identified Retrospectively in Two Patients With Lung Cancer
An international team of clinicians and researchers have described the pathology of the novel coronavirus, or COVID-19, for the first time. Their findings were published by Tian et al in the Journal of Thoracic Oncology. The article’s senior author, Shu-Yuan Xiao, MD, from the University of Chicago ...
NCCN Postpones 2020 Annual Conference, Citing Precautions Against Potential Patient Exposure to COVID-19
The National Comprehensive Cancer Network® (NCCN) announced today that the organization is postponing the NCCN 2020 Annual Conference and preconference programs that were scheduled for March 19–22 in Orlando. The gathering for more than 1,500 oncology professionals was going to feature more than 30 ...
Phenelzine for Biochemical Recurrent Castration-Sensitive Prostate Cancer
A monoamine oxidase A (MAOA) inhibitor in use for decades as an antidepressant demonstrated activity in patients with recurrent prostate cancer, with most toxicities seen with the treatment being reported as mild. These findings were published by Gross et al in Prostate Cancer and Prostatic...
Are Those Who Have Lost a Partner at a Higher Risk of Dying of Melanoma?
Individuals who experience the loss of a partner are less likely to be diagnosed with melanoma—but face an increased risk of dying from the disease, according to research published by Wong et al in the British Journal of Dermatology. While previous studies have suggested a link between various...
AI Algorithms Plus Radiologist Assessment May Help Improve Accuracy in Reading Mammography Results
An ensemble of machine-learning algorithms could help improve the accuracy of breast cancer screenings when used in combination with assessments from radiologists, according to a study published by Schaffter et al in JAMA Network Open. The study was based on results from the Digital Mammography...
Sue Sun Yom, MD, PhD, on HPV-Associated Oropharyngeal Cancer: Challenges in De-intensifying Radiation Therapy
Sue Sun Yom, MD, PhD, of the University of California, San Francisco, talks about the variety of evolving ways to deintensify radiation therapy, the critical need to counsel patients on the risks and benefits, and the ethical importance of respecting patient preferences in choosing their cancer...
Jared Weiss, MD, on Squamous Cell Carcinoma of the Head and Neck: When Standard Therapy is Contraindicated
Jared Weiss, MD, of the University of North Carolina, Chapel Hill, discusses outcomes for patients with stage III or IV disease who are ineligible for the standard treatment of cisplatin plus radiotherapy. His data suggest that treatment with pembrolizumab/radiotherapy instead is tolerable, with...
Jonathan D. Schoenfeld, MD, MPH, on Oral Cavity Cancer: Neoadjuvant Nivolumab With or Without Ipilimumab
Jonathan D. Schoenfeld, MD, MPH, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discusses phase II study results with the PD-1 inhibitor nivolumab or the combination of PD-1/CTLA-4 inhibition with nivolumab/ipilimumab in patients with newly diagnosed untreated oral cavity cancer...
Gopal K. Bajaj, MD, MBA, on Reducing Opioid Use in Patients With Head and Neck Cancer Undergoing Radiotherapy
Gopal K. Bajaj, MD, MBA, of the Inova Schar Cancer Institute, discusses the results of a small study that showed prophylactic gabapentin can be safely and effectively used to significantly reduce pain and the use of opioids in patients undergoing radiotherapy or chemoradiotherapy for head and neck...
David Adelstein, MD, on Guidelines for Treating HPV-Associated Oropharyngeal Squamous Cell Carcinoma
David Adelstein, MD, of the Cleveland Clinic, discusses the hypothesis that treatment can be de-intensified in patients with HPV-associated oropharyngeal cancer and a good prognosis.
Jill Gilbert, MD, on HPV-Associated Oropharyngeal Cancer: Challenges in De-intensifying Systemic Therapies
Jill Gilbert, MD, of Vanderbilt University Medical Center, discusses this ongoing area of investigation and which patients can safely undergo a de-intensification of treatment. Based on two randomized trials, cetuximab should not be substituted for cisplatin as a de-intensification strategy in...
Assuntina G. Sacco, MD, on Head and Neck Squamous Cell Carcinoma: Trial Results on Pembrolizumab and Cetuximab
Assuntina G. Sacco, MD, of the University of California, San Diego, discusses the results of a small phase II study, which suggest that pembrolizumab plus cetuximab may show activity for platinum-refractory/-ineligible patients with recurrent or metastatic head and neck squamous cell carcinoma...
Nadeem Riaz, MD, on Established and Emerging Biomarkers for Immunotherapy in Head and Neck Cancer
Nadeem Riaz, MD, of Memorial Sloan Kettering Cancer Center, discusses the biomarkers that have emerged for immunotherapy and their tumor microenvironments, from PD-L1 staining and the Combined Positive Score to next-generation genomic technologies.
Malnutrition Evaluation Before Oncologic Surgery
The best approach for surgeons to identify malnourished patients with cancer before they have major oncologic surgery may be specifically related to the type of cancer the patient has, according to researchers who found that common definitions of malnutrition do not apply equally to all cancers in...
Carryn M. Anderson, MD, on Reducing Severe Oral Mucositis and Its Effect on Patient Outcomes
Carryn M. Anderson, MD, of the University of Iowa Hospital, discusses the investigational agent GC4419, previously shown to be safe and effective in decreasing the duration, incidence, and severity of oral mucositis in patients receiving concurrent cisplatin and radiation for oral cavity and...
Francis P. Worden, MD, on the Role of Induction Chemotherapy in Laryngeal Preservation
Francis P. Worden, MD, of the University of Michigan Health System Comprehensive Cancer Center, explores the use of novel biomarkers that may help predict response to induction chemotherapy and survival in patients with locally advanced laryngeal cancer.
FDA Approves Isatuximab-irfc–Based Triplet Regimen for Patients With Relapsed or Refractory Multiple Myeloma
On March 2, the U.S. Food and Drug Administration (FDA) approved isatuximab-irfc (Sarclisa) in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. ...
Plasma-Based Tumor Mutational Burden May Predict Response to Immunotherapy in Patients With Metastatic NSCLC
Patients with non–small cell lung cancer (NSCLC) with higher measures of tumor mutations that show up in a blood test generally have a better clinical response to certain immunotherapy treatments than patients with a lower measure of mutations. A clinical trial showed that in cases where liquid...
Weight Gain After Breast Cancer Diagnosis in Australia: Survey Results
New study findings suggest that weight gain after breast cancer is a greater problem than previously thought. The first national survey on weight after breast cancer in Australia, published by Ee et al in BMC Cancer, found close to two-thirds (63.7%) of women reported weight gain at an average of...
FDA Pipeline: Priority Review in Lung Cancer, Breakthrough Therapy Designation in Head and Neck Cancer, and More
This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to brigatinib for the treatment of ALK-positive lung cancer and Breakthrough Therapy designation to a potential first-in-class oral antagonist of inhibitors of apoptosis proteins for the treatment of head and neck...
2020 Head and Neck Cancers Symposium: Adjuvant Everolimus for Advanced Head and Neck Cancer
The mTOR inhibitor everolimus may extend progression-free survival for patients with advanced head and neck cancer who are at high risk for recurrence after standard treatment. Patients enrolled in a randomized phase II trial who received the agent were more likely to be cancer-free 1 year after...
Abbreviated Breast MRI vs Digital Breast Tomosynthesis Screening in Women With Dense Breasts
As reported in JAMA by Christiane K. Kuhl, MD, PhD, and colleagues, the ECOG-ACRIN EA1141 trial has shown that abbreviated breast magnetic resonance imaging (MRI) was associated with a significantly higher invasive breast cancer detection rate vs digital breast tomosynthesis among women with dense...
2020 Head and Neck Cancers Symposium: Nivolumab With or Without Ipilimumab for the Neoadjuvant Treatment of Patients With Oral Cavity Cancer
Results from a new clinical trial suggest that neoadjuvant immunotherapy for oral cavity cancers may elicit tumor regression, which could provide long-term benefit for patients. Findings were presented by Jonathan D. Schoenfeld, MD, MPH, of Dana-Farber/Brigham and Women's Cancer Center, and...
2020 Head and Neck Cancers Symposium: Pembrolizumab Plus Radiotherapy for Platinum-Ineligible Patients With Locally Advanced HNSCC
A new phase II trial has found that the combination of radiation therapy and pembrolizumab led to improved survival outcomes and acceptable toxicity for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). The combination therapy may offer a new treatment option for...
FDA Approves Neratinib/Capecitabine for Pretreated Patients With Metastatic HER2-Positive Breast Cancer
On February 25, the U.S. Food and Drug Administration (FDA) approved neratinib (Nerlynx), a tyrosine kinase inhibitor, in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2–based regimens in the...
Physical Activity and Quality of Life in African American Cancer Survivors
New research suggests that regular exercise may improve the well-being of African American cancer survivors, but most survivors do not meet current recommendations for physical activity. The findings were published by Jennifer Beebe-Dimmer, MPH, PhD, and colleagues in the journal Cancer. Because...
The EHE Foundation Receives $450,000 Award From the Chan Zuckerberg Initiative
The EHE Foundation announced it will receive a $450,000 award from the Chan Zuckerberg Initiative (CZI) to drive progress toward treatments and a cure for epithelioid hemangioendothelioma (EHE), a rare vascular cancer diagnosed in about 20 individuals per year. The award recognizes The EHE...
Dana-Farber Cancer Institute to Establish Riney Family Multiple Myeloma Initiative
Dana-Farber Cancer Institute will establish the Riney Family Multiple Myeloma Initiative to help improve outcomes and accelerate understanding of the underlying biology for the most challenging types of myeloma. The initiative is being established with a $16.5 million gift from Paula and Rodger...
Eileen Smith, MD, Named Chair, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope
Eileen Smith, MD, Medical Director of City of Hope’s Alpha Stem Cell Clinic, Associate Director of the Clinical Research Program, Clinical Professor in the Department of Hematology & Hematopoietic Cell Transplantation, has been appointed the new Chair of the Department of Hematology &...
Update on Project Facilitate at the Oncology Center of Excellence
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Mitchell Chan, PharmD, BCPS, Regulatory Project Manager; Tamy Kim, PharmD, Associate Director of Regulatory ...
Prevent Cancer Foundation Awards $1.1 Million in Cancer Research and Global Grants
The Prevent Cancer Foundation® has announced the funding of eight new United States–based researchers and four new cancer prevention and early detection projects in low- or middle-income countries. Research grants and fellowships awarded this year will increase cancer prevention and early detection ...
